Announced
Synopsis
National Resilience, a biotech company, agreed to acquire bio-manufacturing plant in Allston from Sanofi, a French multinational pharmaceutical company. Financial terms were not disclosed. “We created Resilience to reimagine biopharmaceutical manufacturing through unprecedented investment in technology and a best-in-class team to execute our vision. Covid-19 has exposed critical vulnerabilities in medical supply chains, and today’s manufacturing can’t keep up with scientific innovation, medical discovery, and the need to rapidly produce and distribute critically important drugs at scale. We are committed to tackling these huge problems with a whole new business model," Robert Nelsen, Resilience Founder and Chairman of the Board.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.